GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Cash Conversion Cycle

Shanghai Junshi Biosciences Co (HKSE:01877) Cash Conversion Cycle : -4.38 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Shanghai Junshi Biosciences Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 116.83.
Shanghai Junshi Biosciences Co's Days Inventory for the three months ended in Mar. 2024 was 454.71.
Shanghai Junshi Biosciences Co's Days Payable for the three months ended in Mar. 2024 was 575.92.
Therefore, Shanghai Junshi Biosciences Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was -4.38.


Shanghai Junshi Biosciences Co Cash Conversion Cycle Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Cash Conversion Cycle Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial 304.59 265.38 165.06 426.96 255.29

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 413.69 256.82 - - -4.38

Competitive Comparison of Shanghai Junshi Biosciences Co's Cash Conversion Cycle

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Cash Conversion Cycle falls into.



Shanghai Junshi Biosciences Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Shanghai Junshi Biosciences Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=87.13+314.42-146.26
=255.29

Shanghai Junshi Biosciences Co's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=116.83+454.71-575.92
=-4.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Shanghai Junshi Biosciences Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines